<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Mirapexin preparations; Pramipexole" /><meta name="IX" content="Mirapexin preparations; Pramipexole" /><title>Mirapexin® Prolonged Release: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3079-mirapexin-prolonged-release.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3079-mirapexin-prolonged-release.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3079-mirapexin-prolonged-release.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 08 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP2092-central-nervous-system.htm">4 Central nervous system</a> &gt; <a href="PHP3054-drugs-used-in-parkinsonism-and-related-disorders.htm">4.9 Drugs used in parkinsonism and related disorders</a> &gt; <a href="PHP3056-dopaminergic-drugs-used-in-parkinsons-disease.htm">4.9.1 Dopaminergic drugs used in Parkinson's disease</a> &gt; <a href="PHP3057-dopamine-receptor-agonists.htm">Dopamine-receptor agonists</a> &gt; <a href="PHP3075-pramipexole.htm">PRAMIPEXOLE</a> &gt; <a href="PHP3078-modified-release.htm">Modified release</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3072-pergolide.htm" title="Previous: PERGOLIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3080-ropinirole.htm" title="Next: ROPINIROLE">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a397029.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole Dihydrochloride</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Central Nervous System Agents 28:00 &gt; Antiparkinsonian Agents 28:36 &gt; Dopamine Receptor Agonists 28:36.20 &gt; Nonergot-derivative Dopamine Receptor Agonists 28:36.20.08</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/5570-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Pramipexole</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: P &gt; Interactions of Pramipexole</p></div></li></ul><ul><li><h3>British National Formulary (6)</h3></li><li><a href="PHP3057-dopamine-receptor-agonists.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dopamine-receptor agonists</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson's disease</p></div></li><li><a href="PHP3075-pramipexole.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">PRAMIPEXOLE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson's disease &gt; Dopamine-receptor agonists</p></div></li><li><a href="PHP3076-pramipexole-non-proprietary.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson's disease &gt; Dopamine-receptor agonists &gt; PRAMIPEXOLE</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22pramipexole%22%22pramipexole%22%22restless+legs+syndrome%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (6)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1367.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; P</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/19970-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole Hydrochloride</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antiparkinsonian Drugs &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/7000-a6-10-h.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Sleep-associated movement disorders</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Anxiolytic Sedatives Hypnotics and Antipsychotics &gt; Introduction &gt; Sleep disorders</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/07705.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; P &gt; PR</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-P108.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pramipexole Dihydrochloride</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; P</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E6E3E0R0D1264.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Pramipexole</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; P</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>PRAMIPEXOLE</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int881-pramipexole.htm">Pramipexole</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">Parkinson's disease, used alone or as an adjunct to co-beneldopa or co-careldopa; moderate to severe restless legs syndrome</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="monograph-family: Dopamine receptor agonists" href="PHP3057-dopamine-receptor-agonists.htm">notes above</a>; psychotic disorders; ophthalmological testing recommended (risk of visual disorders); severe cardiovascular disease; risk of postural hypotension (especially on initiation)—monitor blood pressure; <strong>interactions:</strong> Appendix 1 (pramipexole)</p></div> </div> <div class="cL"><h2 class="cM">Renal impairment </h2><ul><li><p>for <em>immediate-release</em> tablets in Parkinson's disease, initially 88 micrograms twice daily (max. 1.57 mg daily in 2 divided doses) if eGFR 20–50 mL/minute/1.73m<sup>2</sup>; initially 88 micrograms once daily (max. 1.1 mg once daily) if eGFR less than 20 mL/minute/1.73 m<sup>2</sup>; if renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR</p> </li><li><p>for <em>immediate-release</em> tablets in restless legs syndrome, reduce dose if eGFR less than 20 mL/minute/1.73 m<sup>2</sup></p> </li><li><p>for <em>modified-release</em> tablets, initially 260 micrograms on alternate days if eGFR 30–50 mL/minute/1.73m<sup>2</sup>, increased to 260 micrograms once daily after 1 week, further increased if necessary by 260 micrograms daily at weekly intervals to max. 1.57 mg daily; avoid if eGFR less than 30 mL/minute/1.73m<sup>2</sup></p> </li></ul> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">use only if potential benefit outweighs risk—no information available</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">may suppress lactation; avoid—present in milk in <em>animal</em> studies</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="monograph-family: Dopamine receptor agonists" href="PHP3057-dopamine-receptor-agonists.htm">notes above</a>; also nausea, constipation, vomiting, weight changes, decreased appetite, hypotension (including postural hypotension), peripheral oedema, dizziness, dyskinesia, hyperkinesia, drowsiness (including <a title="BNF:target-block: Dopamine receptor agonists and driving" href="PHP3057-dopamine-receptor-agonists.htm#PHP3061">sudden onset of sleep</a>), headache, sleep disturbances, confusion, hallucinations, restlessness, visual disturbances; <em>less commonly</em> hiccups, cardiac failure, syncope, pneumonia, dyspnoea, binge eating, compulsive behaviour (see <a title="BNF:target-text: Impulse control disorder caution" href="PHP3057-dopamine-receptor-agonists.htm#PHP3058">notes above</a>), amnesia, delusion, paranoia, pruritus, rash; <em>also reported</em> paradoxical worsening of restless legs syndrome</p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><div class="cG"><div class="cE"><h3 class="cT">Important</h3> <p class="cT">Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows: <br />88 micrograms base ≡ 125 micrograms salt; <br />180 micrograms base ≡ 250 micrograms salt; <br />350 micrograms base ≡ 500 micrograms salt;<br />700 micrograms base ≡ 1 mg salt</p></div></div><ul>  <li><p>Parkinson's disease, <span class="cP">adult</span> over 18 years, initially 88 micrograms 3 times daily, dose doubled every 5–7 days if tolerated to 350 micrograms 3 times daily; further increased if necessary by 180 micrograms 3 times daily at weekly intervals; max. 3.3 mg daily in 3 divided doses</p><div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">During dose titration and maintenance, levodopa dose may be reduced</p></div></div></li>  <li><p>Restless legs syndrome, <span class="cP">adult</span> over 18 years, initially 88 micrograms once daily 2–3 hours before bedtime, dose doubled every 4–7 days if necessary; max. 540 micrograms daily</p></li> </ul></div></div> <div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Repeat dose titration if restarting treatment after an interval of more than a few days</p></div></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP3076-pramipexole-non-proprietary.htm#PHP3076-pramipexole-non-proprietary" title="Pramipexole">Pramipexole</a></li><li><a href="PHP3077-mirapexin.htm#PHP3077-mirapexin" title="Mirapexin®">Mirapexin®</a></li></ul><div id="PHP3078-modified-release" style="margin: 0 0 0 20px;"><h1 class="title">Modified release</h1><div id="PHP3079-mirapexin-prolonged-release" style="margin: 0 0 0 20px;"><h1 class="title">Mirapexin® Prolonged Release <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10070">Boehringer Ingelheim</a>)</span><span> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Tablets</strong>, m/r, pramipexole 260 micrograms, net price 30-tab pack = £28.65; 520 micrograms, 30-tab pack = £57.30; 1.05 mg, 30-tab pack = £114.60; 1.57 mg, 30-tab pack = £171.90; 2.1 mg, 30-tab pack = £229.20; 2.62 mg, 30-tab pack = £286.50; 3.15 mg, 30-tab pack = £343.80. Label: 10, 25, counselling, driving, see <a title="BNF:target-block: Dopamine receptor agonists and driving" href="PHP3057-dopamine-receptor-agonists.htm#PHP3061">notes above</a></p><div class="cG"><div class="cE"><h3 class="cT">Important</h3> <p class="cT">Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows: <br />260 micrograms base ≡ 375 micrograms salt;<br />520 micrograms base ≡ 750 micrograms salt;<br />1.05 mg base ≡ 1.5 mg salt;<br />1.57 mg base ≡ 2.25 mg salt;<br />2.1 mg base ≡ 3 mg salt;<br />2.62 mg base ≡ 3.75 mg salt;<br />3.15 mg base ≡ 4.5 mg salt</p></div></div><p class="cR"><strong>Dose </strong>Parkinson's disease (with or without co-beneldopa or co-careldopa), <span class="cP">adult</span> over 18 years, initially 260 micrograms once daily, dose doubled every 5–7 days to 1.05 mg once daily; further increased if necessary by 520 micrograms daily at weekly intervals; max. 3.15 mg once daily</p><div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">During dose titration and maintenance, levodopa dose may be reduced according to response</p></div></div></div></div></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3072-pergolide.htm">Previous: PERGOLIDE</a> | <a class="top" href="PHP3079-mirapexin-prolonged-release.htm#">Top</a> | <a accesskey="]" href="PHP3080-ropinirole.htm">Next: ROPINIROLE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>